CXCL12 and myeloid sarcoma: As previously mentioned, CXCL12 CSF levels and CXCL12 CNS histological changes positively correlate with disease severity, which indicates that CXCL12 could be used as a biomarker for MS [14,18], but there are limited data on CXCL12 serum levels.